Sponsor content

Collaborative Research and Licensing Opportunity:Monoclonal Antibodies that Neutralize Norovirus

New chimpanzee-human chimeric monoclonal antibodies were developed, which specifically bind to Norovirus and have therapeutic and immunoprophylactic potential.

Vaccines and therapies to prevent and treat Norovirus infections do not exist, despite the worldwide prevalence of Norovirus infections. Outbreaks of human gastroenteritis attributable to Norovirus commonly occur in group setting, such as hospitals, nursing homes, schools, dormitories, cruise ships and military barracks. This technology relates to chimpanzee-human chimeric monoclonal antibodies, which specifically bind to Norovirus and have therapeutic potential. The antibodies that were tested in a primate model of infection have shown protection against Norovirus. These Norovirus antibodies may have application as immunoprophylaxis to protect individuals from infections or as a possible treatment for infected individuals, or can be used to develop a diagnostic for detection of norovirus infections.

Potential Commercial Applications:

  • Therapeutics
  • Vaccine
  • Diagnostics

Competitive Advantages:

  • First-in-class as there are no existing vaccines or therapeutics against Norovirus infections
Publications:

Chen Z, et al., Development of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis, J Virol. 2013 Sep; 87(17):9547-57. [PMID 23785216].

Intellectual Property:

HHS Reference No. E-226-2011/0:

U.S. 61/763,879;

PCT/US2014/015809;

EP No. 14706239.2;

U.S. 14/76,274;

U.S. 15/359,438

Collaborative Research Opportunity:The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this invention, especially for GMP manufacture and clinical evaluation.

Contact: Dr. Jenish Patel, tel. (240) 669-2894, jenish.patel@nih.gov


Go to the profile of NIAID Technology Transfer and Intellectual Property Office

NIAID Technology Transfer and Intellectual Property Office

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebola, influenza, methicillin-resistant Staphylococcus aureus and HIV/AIDS), biodefense (e.g., smallpox and anthrax), and immune-mediated diseases (e.g., asthma and allergy).

No comments yet.